u/ahmed_iyer

Correction: that threshold is your ICB’s, not a national one. They differ and they change by year.

preclinical enthusiasm is not clinical evidence

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim.

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

Not convinced. A high purity figure with no identity confirmation tells you the sample is homogeneous, not that it is what you ordered.

Open-label extensions lose their randomisation. Anybody still enrolled at week 104 is a selected group and the numbers describe that group.

Week 29 was the first time the scale moved after a five-week stall. I changed nothing in that window.

Yes. I stepped to 12.5 because the calendar said so, not because anything needed fixing, and I regretted it for a fortnight.

Cosigning the four-week thing. It is a minimum interval, and treating it as a schedule to keep up with is how people end up miserable at 12.5.

Agreed on comparators. "Superior" means nothing until you know superior to what and at what dose.

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

This matches mine. Milder fatigue than I expected, and what there was settled inside a fortnight of each step.

In England, specialist weight management services are commissioned locally, so eligibility criteria and waiting times differ by ICB. There is no single national threshold to quote.

Push back: an open-label extension tells you about the people who stayed.

anders_vermeulen is right about the programme names. They are different populations with different endpoints.

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.

Disagree with the conversion table. There is no validated equivalence between the two molecules and posting one as though there is does real damage.

A private prescription is an independent route: it does not affect NHS list position, and it is not a step in the same pathway.

Agreed — and keeping the letters with dates is what makes any later challenge possible.

Sent a vial to Janoshik: 98.2% against a claimed 98.0%, with the mass confirming the sequence. Both halves mattered to me.

SURPASS is the diabetes programme and reports glycaemic endpoints

Not convinced — the US threads are a different system entirely and importing their advice here does real harm.

intention to treat versus completers changes the number substantially

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

Short peptides in solution are subject to hydrolysis and, depending on sequence, oxidation. Storage state and time in solution are practical variables that this board almost never discusses.

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

Right, and reading the actual supply notice rather than the coverage of it saves a fortnight of speculation.

a lot of people plateau nicely at 10mg and never need 15

Small fix — that is the Scottish pathway. The post is asking about England and the answer is different.

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

a lot of people plateau nicely at 10mg and never need 15

Yes — 10mg being a genuine landing place for a lot of people is underrated. There is no medal for 15.

zepbound and mounjaro are the same compound with different labels

Careful with "everyone tolerates it better". The people it did not suit stop posting, which makes this board look calmer than the drug is.

Have you seen the current threshold published by your ICB?

Disagree.

This is why national advice does not work here. It is commissioned locally and it varies.

How long have you been on the list, and from what date?

a mean is not a promise